With improved understanding of the regulatory network of NLRP3 inflammasome, and better understanding of the pharmacological mechanism of natural products, more clinical trials on the use of natural products in the treatment of DKD are expected in the future. This evidence concerns the gene NLRP3 and diabetic kidney disease.